Natural products (NPs) have been at the origin of several established drugs against tuberculosis (TB). Although the current clinical TB pipeline does not feature any candidates derived from new NP scaffolds, numerous novel NPs or NP analogs have been discovered in the recent past with promising activity against Mycobacterium tuberculosis (Mtb). This includes newly discovered structures as well as known NP classes that had not been previously recognized to be active against Mtb. These compounds could help to replenish the dry clinical TB pipeline and, thus, contribute to improvements in the treatment of a devastating disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drudis.2016.11.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progress towards effective vaccines for Chlamydia trachomatis.
Curr Opin Infect Dis
February 2025
Department of Molecular Genetics and Microbiology, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA.
Purpose Of Review: Effective vaccines to prevent sexually transmitted Chlamydia trachomatis (Ct) infection have eluded researchers for decades. However, recent studies of a promising vaccine in human trials, and emerging understanding of the complexity of the natural immune response to infection have provided hope for the eventual approval of a vaccine. This review highlights recent progress toward developing effective vaccines for Ct.
View Article and Find Full Text PDFDrug screening for ischemic stroke using larvae and adult zebrafish model: a review.
Lab Anim Res
January 2025
Physiology, Animal Development, and Biomedical Science Research Group, School of Life Sciences and Technology, Institut Teknologi Bandung, Jl. Ganesha 10, 40132, Bandung, Indonesia.
Ischemic stroke (IS) is the most recorded case of stroke that is caused by decreased blood flow to the brain. Nowadays, therapeutical agents for IS are limited and they have not shown maximum clinical results. Therefore, the exploration of new candidates for IS treatment continues to be done.
View Article and Find Full Text PDFEmpowering Futures: The Impact of Surgical Research Pipeline Programs on Undergraduate Career Development.
J Surg Educ
December 2024
Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address:
Purpose: Surgical research pipeline programs provide a unique insight into academic surgery, offering a distinctive opportunity for aspiring future surgeons and medical professionals to identify suitable mentorship. The objective of this study was to determine the impact of an academic summer research, shadowing, and mentorship program on undergraduate students with interest in the fields of medicine and surgery.
Methods: We conducted a convergent mixed methods study on undergraduate students who participated in the Surgery Undergraduate Research Experience (SURE) program from 2017 to 2022, excluding the 2020 cohort as their experience was highly impacted by COVID-19.
Computational Methods for Data Integration and Imputation of Missing Values in Omics Datasets.
Proteomics
December 2024
Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Molecular profiling of different omic-modalities (e.g., DNA methylomics, transcriptomics, proteomics) in biological systems represents the basis for research and clinical decision-making.
View Article and Find Full Text PDFCanine models of inherited retinal diseases: from neglect to well-recognized translational value.
Mamm Genome
December 2024
Division of Experimental Retinal Therapies, Department of Clinical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Large animal models of inherited retinal diseases, particularly dogs, have been extensively used over the past decades to study disease natural history and evaluate therapeutic interventions. Our group of investigators at the University of Pennsylvania, School of Veterinary Medicine, has played a pivotal role in characterizing several of these animal models, documenting the natural history of their diseases, developing gene therapies, and conducting proof-of-concept studies. Additionally, we have assessed the potential toxicity of these therapies for human clinical trials, contributing to the regulatory approval of voretigene neparvovec-rzyl (Luxturna) by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with confirmed biallelic mutation-associated retinal dystrophy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!